Treatment of bioactive compound VS 8 can induce human HCC cell line HepG2 cell apoptosis and inhibit the expression of EMT-induced transcription factors in CD44+CD133+ cancer stem cells, by inhibiting VEGF/VEGFR-2 signaling pathway (104). The gene discussed is VEGFA; the disease is hepatocellular carcinoma.